Revascularization as a treatment to improve renal function

Helen V Alderson
James P Ritchie
Philip A Kalra

The University of Manchester, Manchester Academic Health Sciences Centre, Vascular Research Group, Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK

Abstract: An aging atherosclerosis-prone population has led to an increase in the prevalence of atherosclerotic renovascular disease (ARVD). Medical management of this disease, as with other atherosclerotic conditions, has improved over the past decade. Despite the widespread availability of endovascular revascularization procedures, there is inconsistent evidence of benefit in ARVD and no clear consensus of opinion as to the best way to select suitable patients for revascularization. Several published randomized controlled trials have attempted to provide clearer evidence for best practice in ARVD, but they have done so with varying clarity and success. In this review, we provide an overview of ARVD and its effect on renal function. We present the currently available evidence for best practice in the management of patients with ARVD with a particular focus on revascularization as a treatment to improve renal function. We provide a brief overview of the evidence for revascularization in other causes of renal artery stenosis.

Keywords: renal artery stenosis, revascularization, atherosclerotic renovascular disease, fibromuscular dysplasia

Introduction
In the Western world, over 90% of cases of renal artery stenosis (RAS) are caused by atherosclerotic renovascular disease (ARVD). This is a heterogeneous condition that can present in various ways, from clinically silent disease to flash pulmonary edema or anuric acute kidney injury (AKI). Strong associations exist between the presence of ARVD and other atherosclerotic diseases, hypertension, and chronic kidney disease (CKD). An aging population means that this is an increasing problem in the Western world. Endovascular renal revascularization procedures have been available for over 3 decades. Despite an extensive literature of case reports and randomized controlled trials (RCTs), there is little robust evidence for revascularization, even in clinical scenarios where international guidelines support an interventional approach. However, interpretation of the published literature is confounded by the complex pathogenesis and the range of clinical presentations of ARVD. As such, the debate over merits of intervention continues. Although ARVD is the most common cause of RAS, other conditions are recognized, with fibromuscular disease being the most common of these in the Western world. Here, the clinical consensus regarding revascularization is more positive. This review focuses on revascularization for ARVD with separate, more limited consideration given to other causes of RAS.
Epidemiology of ARVD

Assessing the true population prevalence of ARVD is difficult; it may be a clinically silent condition and there is no screening program in place. Where prevalence studies have been published, confounding due to high rates of co-existent diabetes, hypertension, and vascular comorbidity is often present. The effect of comorbidity can be demonstrated by comparing the prevalence rate of 20% (95% confidence interval [CI] 15.4–25.5) seen in patients with diabetes and hypertension to the figure of 6.8% seen in a Doppler ultrasound screening study of 834 community-based elderly ‘free-living’ individuals in Forsyth county, NC, USA. The incidence of ARVD has appeared to vary over time, most likely due to evolving physician awareness and access to diagnostic tools. The largest data are drawn from interrogation of the US Medicare 5% denominator file. Here, in the period 1999–2001, the incidence of ARVD was 3.7/1,000 patient-years in patients aged over 67 years. Rates of diagnosis increased until the mid-2000s, due perhaps to the increasing enthusiasm for undertaking revascularization procedures before the results of RCTs into the condition were available. Although no subsequent analysis of the Medicare data has been undertaken, United States Renal Data System (USRDS) reports have since shown a reduction in cases of end-stage kidney disease (ESKD) secondary to ARVD (reduction from 1.7% to 1.3% between 2004 and 2009).

Although ARVD is the most common cause of RAS in the West (with post-vasculitic stenosis the most common cause in parts of Asia), there are no robust data to suggest ethnic variation in prevalence. In the population screening study discussed above, equal proportions of White and African American subjects had significant disease, and in a retrospective analysis of over 300 patients screened for ARVD (40% non-White), Caucasian ethnicity was not identified as an independent predictor for the presence of RAS. As no study has compared Caucasian and Asian patients, it is impossible to pass precise comment. However, a markedly lower proportion of Japanese patients with other macrovascular disease have abnormal renal vessels.

Prognosis in ARVD

Mortality rates are high in ARVD, with patients six times more likely to die of a cardiovascular event than progress to ESKD. The earlier Medicare analysis showed that annual mortality rates in patients with ARVD (16.3%) were almost three times greater than general Medicare patients without the condition. Improved understanding of how best to manage these patients has likely contributed to reducing this gap, with an average annual mortality rate of 8% in ARVD patients in the most recently published RCT data. Several series have demonstrated that the presence of ARVD is an adverse prognostic factor independent of the presence of other atherosclerotic diseases. In coronary artery disease, a 1.5-times higher risk for death is associated with the presence of ARVD, whereas it indicates a 3-times higher risk in patients with peripheral vascular disease. This relationship appears to exist in both directions, with ARVD patients investigated for other macrovascular disease having an increased 4-year mortality rate where a greater degree of extra-renal disease exists.

Data regarding survival in patients with ARVD who reach dialysis are conflicting. A single-center study of over 680 hemodialysis patients described significantly increased mortality following initiation of dialysis in ARVD patients compared with other primary disease groups. However, another large-scale Medicare and USRDS analysis noted a significantly reduced risk for death following initiation of dialysis in patients with ARVD when adjusted for comorbid conditions. It remains unclear whether the apparent increase in risk described in the initial study is simply a reflection of comorbid atherosclerotic disease, or if the reduced risk in the latter study is a limitation of the coded data that were available.

Renal function

With current management, the average annual rate of loss of renal function in ARVD in both RCT and ‘real-world’ data is between 1 and 2 mL/min/1.73m²/year, with approximately 4% of patients progressing to renal replacement therapy each year. Registry data suggest that ARVD is the primary disease in 6.7% of incident UK dialysis patients. However, the pathogenesis of renal parenchymal damage in ARVD is complex; the extent of renal dysfunction is not explained solely by the degree of RAS. Historic observational studies have shown that renal artery lesions commonly progress, although this has been markedly attenuated following the introduction of statins. However, there is no clear relationship between vascular anatomy and rate of change in renal function. Cheung et al studied 142 patients with unilateral renal artery occlusion and demonstrated that there was no relationship between contralateral renal artery anatomy and baseline renal function or rate of change in renal function. Intra-renal ischemia, microvascular disruption, and associated renal atrophy appear to be more important than the degree of stenosis in determining functional outcomes in ARVD.
The identification of patients with ‘hibernating parenchyma’ may help to select those who are likely to benefit from revascularization. This term was first coined by Tuttle\(^2\) and is used to distinguish those kidneys that may improve with revascularization from those that have suffered irreversible parenchymal damage, and that show no improvement.

**Treatment for ARVD**  
**Medical therapy**

There is a limited evidence base for the medical management of patients presenting with ARVD. Treatment with angiotensin blockade\(^3\)-\(^4\) and lipid-lowering therapy\(^2\) is accepted as a minimum standard of care, and there is consensus that other vascular risk reduction measures should be applied. Given differences in medical therapy within and between published RCT data, direct comparison between studies is not practical. However the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial included standardized medical therapy of anti-platelet agent and lipid-lowering therapy, with angiotensin II blockade as first-line anti-hypertensive therapy.\(^2\)

**Revascularization**

Surgical revascularization for ARVD has effectively been consigned to history, at least in cases without complicated anatomy, as percutaneous intervention has been shown to produce comparable angiographic results\(^2\) without suffering the 10% mortality rate described with open reconstruction.\(^2\)

Standard practice is now accepted to be percutaneous angioplasty with bare metal stenting (percutaneous transluminal renal angioplasty with stenting [PTRAS]), with stents significantly reducing rate of restenosis compared with angioplasty alone, especially for ostial lesions.\(^2\)-\(^4\) Although PTRAS is considered relatively safe in expert hands, around 3% of patients experience a serious complication such as major hemorrhage or dissection, and less serious complications such as a transient deterioration in renal function or groin hematoma may occur in around 10% of cases.\(^2\) In light of these procedural risks, it is important to determine which patients are most likely to benefit from revascularization procedures and to perform them on this select cohort rather than in all patients with ARVD. Historical registry data indicate that revascularization procedures were performed in around 16% of cases of ARVD;\(^3\) although this figure has fallen markedly in light of negative trials into PTRAS.\(^3\) What remains unclear is which patients are currently being revascularized. Whilst published trials have considered change in blood pressure and renal function as primary endpoints, with death and cardiovascular events as secondary endpoints, international guidelines consider presentation with flash pulmonary edema, refractory hypertension, and progressive CKD as possible indications for renal artery stenting.\(^3\) Whilst there is support for PTRAS in patients presenting with flash pulmonary edema\(^5\) and oligo-anuric AKI,\(^6\) support for these guidelines is not universal.\(^7\) Furthermore, arguments exist to support PTRAS to enable the institution of angiotensin-converting enzyme inhibitors\(^8\) or to treat chronic heart failure.\(^9\)

**Revascularization and its effect on renal function**  
**Progression of CKD**

A number of case series and RCTs have now examined the relationship between progression of CKD and revascularization in ARVD. Although some case series showed a trend towards reduced rates of decline in renal function following endovascular revascularization procedures,\(^2\)-\(^6\) other studies have suggested less convincing evidence of benefit.\(^1\)-\(^2\) Beutler et al\(^1\) were only able to demonstrate benefit in those with declining renal function pre-intervention. The uncertainty and conflicting findings of these series paved the way for a number of RCTs of revascularization in ARVD.

Prior to the landmark Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) study,\(^8\) there were five published RCTs comparing percutaneous renal artery revascularization with medical therapy in patients with ARVD.\(^3\)-\(^5\) Renal function varied from normal to moderate CKD, and hypertension was invariably present. These trials were all small, the largest having only 106 patients, and follow-up periods were short. The earlier trials have looked at angioplasty rather than stent insertion and were inadequately powered to assess major functional outcomes. These trials failed to ascertain whether or not revascularization is superior to medical therapy in the management of RAS and to provide clearer indications for its use. A later meta-analysis of the first three RCTs\(^4\)-\(^6\) (n=210) showed that, although there was no benefit in blood pressure at 6 months, there was a greater mean improvement in blood pressure in those who underwent angioplasty.\(^4\) The Dutch-led Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function (STAR) study was published just prior to ASTRAL. A high proportion of patients randomized to stenting did not receive the procedure and no differences were observed in terms of blood pressure control or renal function.\(^7\) Hence, none of these studies has been able to demonstrate a significant difference in progression of renal function in patients receiving medical therapy compared
with those undergoing revascularization procedures. These trials are summarized in Table 1.

The ASTRAL trial was designed to try and determine whether revascularization is of benefit in ARVD. A total of 806 patients with ARVD (average 76% stenosis) were recruited and randomized to either medical therapy alone or medical therapy plus endovascular revascularization. Median follow-up was 33.2 months, with a minimal follow-up of 12 months for all patients. The primary endpoint was change in renal function, with change in blood pressure, cardiovascular events, renal events, and all-cause mortality the main secondary endpoints. The study found no difference in the primary endpoint of change in renal function between the two groups. Similarly, blood pressure fell equally in both groups and there was no difference in cardiovascular events or mortality between the two groups. The ASTRAL trial concluded that endovascular revascularization does not improve renal function, blood pressure control, cardiovascular events, or mortality in patients with ARVD (Figures 1 and 2).

However, the ASTRAL trial had limitations. Importantly, patients were only eligible for enrollment if their managing clinician was uncertain about whether or not they would benefit from revascularization. Although impossible to quantify, it is probable that patients presenting with ARVD and rapidly deteriorating renal function or hypertension that was difficult to control were not enrolled in this study but rather were referred directly for revascularization by their clinicians outside of the trial.

ASTRAL has been criticized on a number of counts. First, there was no centralized verification of the degree of RAS in enrolled patients (so some lesions may have been overestimated). Moreover, the clinical equipoise of the trial meant that patients with normal renal function and relatively minor disease were included. Critics of the trial felt the inclusion of such low-risk patients may have led to bias in the results, as this group of patients would be unlikely to demonstrate progressive renal decline regardless of whether or not revascularization procedures were undertaken. However, post hoc analysis of subgroups with severe disease also failed to demonstrate significant improvement with stenting, leading some to assert that benefits previously attributed to endovascular revascularization could be achieved with best medical management. Whatever the criticisms of ASTRAL may be, it showed that there is little clinical benefit to be gained from revascularization in patients presenting with stable renal function and ARVD and certainly little to justify the procedural risks in this group. The optimal management in other groups is still an area for ongoing debate and research.

The publication of the ASTRAL results has led to a major change in practice, with the rate of renal revascularization falling to 30% of the pre-trial results in the UK, with similar reductions in the USA. Despite its shortcomings, ASTRAL demonstrated that, in most patients, stenting for ARVD does not benefit renal function. The continued uncertainty regarding other clinical outcomes, such as major cardiovascular and renal events, was the basis for the design of the recently published CORAL trial. 

CORAL opened in 2004 and completed recruitment in 2012. The trial randomized 947 patients with >60% atherosclerotic RAS to standardized medical management or medical management plus endovascular revascularization. The degree of RAS in all patients was centrally verified in a core radiology laboratory. In order to determine benefit in relation to major renal and cardiovascular endpoints, there was a composite of cardiovascular and renal death, cardiovascular events (myocardial infarction [MI], stroke, congestive cardiac failure), increasing serum creatinine, or initiation of renal replacement therapy. Over a mean follow-up of 43 months, there was no difference in the rate of the composite endpoints between the stent plus medical therapy and the medical therapy alone group (35.1% and 35.8%, respectively), hazard ratio with stent 0.94 (95% CI 0.76–1.17; P=0.58). In the subgroup of patients with more severe stenosis (>80%), there was also no benefit with stenting in addition to medical therapy. Furthermore, there was no difference in the component endpoints or all-cause mortality between the two groups. The CORAL trial was able to conclude that stenting placement for ARVD does not confer benefit with respect to clinical events when added to medical therapy in those patients with ARVD and hypertension or CKD.

AKI
There are case reports of rescue from dialysis of patients presenting with anuric AKI secondary to ARVD. The general consensus of opinion is in favor of intervention in these individuals, although no further evidence base exists to support this. It is possible that patients presenting in this way fall into two groups. First there are those patients presenting with an acute renal artery occlusion or very high-grade RAS; in these individuals urgent revascularization is needed in order to restore renal blood flow and perfusion. In other patients, there may be a background of chronic ischemia and then an acute insult that results in an episode of AKI. These kidneys are chronically under-perfused and ischemic and therefore may be less likely to respond to an intervention.
<table>
<thead>
<tr>
<th>Trial title and author</th>
<th>Year</th>
<th>Number of patients</th>
<th>Study design</th>
<th>Study endpoints</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized comparison of percutaneous angioplasty vs continued medical therapy for</td>
<td>1998</td>
<td>55</td>
<td>Patients on two or more antihypertensive medications and minimal 50% RAS</td>
<td>Primary endpoint: change in blood pressure. Secondary endpoints: renal function and major outcomes (death and cardiovascular events)</td>
<td>Significant fall in BP in angioplasty group in those with bilateral RAS. No difference in secondary endpoints. Significant complication rate (11/40 patients) in intervention group.</td>
</tr>
<tr>
<td>hypertensive patients with atheromatous renal artery stenosis Webber et al for</td>
<td></td>
<td></td>
<td>Randomized to angioplasty plus medical therapy vs continued medical therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scottish and Newcastle Renal Artery Stenosis Collaborative Group Blood Pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome of Angioplasty in Atherosclerotic Renal Artery Stenosis: A Randomized Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plouin et al for Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group</td>
<td></td>
<td></td>
<td>Primary endpoint: 24-hour ambulatory BP at follow-up. Secondary endpoints: treatment score and complication rate</td>
<td></td>
<td>Angioplasty potentially drug sparing; 60% reduction in probability of treatment score ≥2 at 6 months. More complications in angioplasty group.</td>
</tr>
<tr>
<td>Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular</td>
<td>1999</td>
<td>84</td>
<td>Patients with ostial RAS of &gt;50% Randomized to PTA vs PTAS</td>
<td>Primary patency at 6 months</td>
<td>Primary success 57% in PTA vs 88% in PTAS group. 29% primary patency at 6 months in PTA vs 75% in PTAS group. No clinical difference at 6 months (intention to treat). In PTA group, 12 required secondary stenting.</td>
</tr>
<tr>
<td>disease: a randomized trial van de Ven et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Effect of Balloon Angioplasty on Hypertension in Atherosclerotic Renal Artery</td>
<td>2000</td>
<td>106</td>
<td>Patients with hypertension and RAS &gt;50% Randomized to angioplasty plus</td>
<td>Primary endpoint: BP at 3 and 12 months. Secondary endpoints: treatment score, renal function, renal artery patency, and complications</td>
<td>No difference in primary endpoint or renal function. Mild drug-sparing effect in angioplasty group. 22 patients crossed over into angioplasty group.</td>
</tr>
<tr>
<td>Stenosis van Jaarsveld et al for Dutch Renal Artery Stenosis Intervention Co-operative (DRASTIC)</td>
<td></td>
<td></td>
<td>medical therapy vs medical therapy alone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis and Impaired</td>
<td>2009</td>
<td>64</td>
<td>Patients with CrCl &lt;80 mL/min and RAS &gt;50% Randomized to stent insertion</td>
<td>Primary endpoint of ≥20% reduction in CrCl. Secondary endpoints: safety, cardiovascular morbidity, and mortality</td>
<td>No significant difference in primary endpoint (reached in 16% of stent and 22% medication-only group). No difference in secondary endpoints except complications. Two stent-related deaths. Underpowered.</td>
</tr>
<tr>
<td>Renal Function: A Randomized Trial (STAR) Bax et al</td>
<td></td>
<td></td>
<td>plus medical therapy vs medical therapy alone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revascularization versus Medical Therapy for Renal Artery Stenosis Wheatley et al</td>
<td>2009</td>
<td>806</td>
<td>Patients with significant RAS and clinician unsure of best treatment</td>
<td>Primary endpoint: renal function Secondary endpoints: BP, cardiovascular and renal events, mortality</td>
<td>No significant difference between groups in any endpoint. Significant complication rate in intervention group.</td>
</tr>
<tr>
<td>for Angioplasty and STenting for Renal Artery Lesions (ASTRAL) study group</td>
<td></td>
<td></td>
<td>Randomized to revascularization plus standard medical therapy vs standard</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medical therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BP, blood pressure; CrCl, creatinine clearance; PTA, percutaneous angioplasty alone; PTAS, percutaneous angioplasty plus stent; RAS, renal artery stenosis; vs, versus.
Rapidly declining renal function

The published guidelines support revascularization in patients with rapidly declining renal function, but the latter has not been consistently defined, and there remains very little evidence of benefit to support such an approach. The ASTRAL trial examined a subgroup of 96 patients with rapidly declining renal function (defined as 20% and/or 100 µmol/L increase in serum creatinine over 1 year). Although at follow-up those patients that underwent revascularization had a lower serum creatinine than those on standard medical therapy, this difference was not statistically significant.

In a single-center assessment of 127 patients undergoing revascularization outside of the ASTRAL trial in a UK center,
Valluri et al\textsuperscript{23} were only able to demonstrate a suggestion of benefit in those with rapidly deteriorating renal function, and this was not statistically significant. There was no improvement in cardiovascular outcomes or mortality. However, the authors failed to account for use of angiotensin blockade post-intervention, which may have confounded the results.

A recent single-center retrospective analysis looked at different clinical presentations of ARVD. A total of 467 cases of patients with >50% unilateral RAS were reviewed, inclusive of those enrolled in clinical trials. High-risk clinical presentations were defined as flash pulmonary edema, refractory hypertension, and rapidly declining renal function. The 237 patients with high-risk presentations were compared with the 230 patients with none of these features. The authors demonstrated a mortality benefit in those patients who presented with flash pulmonary edema and underwent revascularization compared with those with the same clinical presentation who had no radiological intervention (hazard ratio 0.4, 95% CI 0.2–0.9; \( P=0.01 \)). When considered in combination, there was a benefit in terms of mortality and cardiovascular events in those with both rapidly declining renal function and refractory hypertension undergoing revascularization compared with those with no intervention, but such positive results were not seen for either clinical presentation occurring alone. There was no benefit in terms of rate of decline in renal function in any group.\textsuperscript{14} Although there are limitations to this retrospective data, the results help to ascertain the benefits of revascularization in terms of mortality and cardiovascular events in patients with high-risk presentations. It also questions the utility of change in renal function as a clinical endpoint in ARVD. Perhaps further studies will shed more light on the utility of revascularization as a treatment to improve renal function or maybe it is now time to consider different clinical endpoints and to focus on a better description of the population likely to benefit from revascularization in ARVD.

In order to determine whether the subgroup of patients with rapidly deteriorating renal function are likely to benefit from revascularization, a patient-level meta-analysis of ASTRAL, CORAL, and STAR will most probably be needed.

**Developments in revascularization**

There appears to be no universal benefit of revascularization in ARVD, and there are significant risks associated with interventional procedures. This has led to a number of studies focusing on ways to predict or enhance individual response to intervention.

A meta-analysis of studies in ARVD found no clinical characteristics that were able to reliably predict outcomes following revascularization.\textsuperscript{54} However, a number of studies have looked at other ways of predicting response to revascularization in ARVD, either through imaging techniques or biomarker measurement.

Cheung et al\textsuperscript{55} looked at parenchymal volume assessed via magnetic resonance imaging (MRI) scanning and isotopic single kidney glomerular filtration rate (GFR) in 50 patients with >50% RAS who underwent revascularization plus medical therapy or medical therapy alone. In their study, a disproportionately high ratio of parenchymal volume to single-kidney GFR (PV:SKGFR – a possible reflection of ‘hibernating parenchyma’) was predictive of improvement in GFR post-revascularization. Although clinicians may take note of renal size in deciding the potential benefit of revascularization for an individual, there is no routine assessment of renal reserve.

Other imaging techniques have shown variable promise in determining which individuals may benefit from revascularization. It has been suggested that determination of renal resistive index with duplex Doppler ultrasound scanning may indicate response to revascularization.\textsuperscript{56,57}

Blood oxygen level-dependent (BOLD) magnetic resonance scanning has been developed as a non-invasive investigation that may help predict response to revascularization. It is a sensitive technique to detect changes in tissue deoxyhemoglobin. Animal studies have shown that BOLD imaging reliably detects changes in intra-renal oxygenation with varying degrees of reduction in renal blood flow.\textsuperscript{58} A clinical study of 28 patients demonstrated that high BOLD signal to single kidney isotopic GFR was predictive of improvement in renal function following revascularization,\textsuperscript{59} thereby suggesting that BOLD imaging may provide a way of again detecting so-called ‘hibernating parenchyma.’

Various other studies have looked for factors that may help predict response to revascularization in individuals. A small study (n=27) by Silva et al\textsuperscript{60} measured pre- and post-intervention brain natriuretic peptide (BNP) levels and blood pressure response to endovascular revascularization. Pre-intervention BNP levels of >80 pg/mL were predictive of a response to revascularization (\( P=0.001 \)). However, the small study numbers and specified endpoint of the analysis should caution extrapolation of these results pending further research.

One explanation for why renal function does not consistently improve following renal revascularization is that cholesterol micro-embolization may accompany...
the procedure. In an RCT of 100 patients undergoing percutaneous revascularization procedures for RAS, there was a post-procedure fall in estimated GFR (eGFR) in all patients, regardless of whether or not an embolic protection device was deployed or the glycoprotein IIb/IIIa inhibitor abciximab was administered. However, with combination therapy, no post-procedure fall in eGFR was observed, suggesting a potential benefit for such therapies in ameliorating cholesterol embolization post-intervention.

In the context of ischemia, neovascularization within the microvasculature occurs to sustain tissue perfusion. The microvasculature maintains plasticity and is able to regulate angiogenesis in response to changes in local metabolic requirements. Vascular endothelial growth factor (VEGF) is secreted in response to acute hypoxia and is essential for the preservation of this microvasculature. However, in the context of prolonged hypoxia, VEGF secretion is diminished, presumably because injured cells are no longer able to secrete this cytokine. This leads to a cascade of poor microvascular repair and increasing renal injury. In animal studies, administration of VEGF prior to revascularization improved post-procedure blood pressure and renal function. This was felt to be due to improvements in the renal microcirculation.

Revascularization for other causes of RAS

ARVD is the leading cause of RAS in the Western world, followed by fibromuscular dysplasia. In contrast, vasculitic disease (variably Takayasu’s arteritis) is the most common cause in South-East Asia. Other diseases, such as middle aortic syndrome, embolic phenomenon, and arterial dissection are important, albeit less common, causes of RAS. Hypertension is generally a more significant clinical problem than renal dysfunction in these conditions. In fibromuscular dysplasia and Takayasu’s disease, evidence for benefit from revascularization is more consistent than in ARVD, but this is due, at least in part, to the fact that control of hypertension is the main treatment goal, and robust trials are still lacking.

Fibromuscular dysplasia

Fibromuscular dysplasia is a non-atherosclerotic non-inflammatory condition that most commonly affects women aged 15–60 years. The most usual presentation is with renovascular hypertension, although stroke and cranial nerve palsies are well recognized and it can affect any arterial bed in the body. There are no RCT data to guide management in this condition, and the prospective studies that do exist report widely varying success in terms of successful control of hypertension and recurrence of stenotic lesion. A meta-analysis and systematic review of 70 studies reported a 46% (95% CI 40–52) cure rate with angioplasty, with the greatest success observed amongst young patients with a short duration of hypertension and where there was successful obliteration of the pressure gradient with treatment. It is possible that co-existence of essential hypertension in older patients reduced the success of revascularization procedures in these studies. Revascularization is recommended as first-line therapy for young patients and those with severe disease, refractory hypertension, or deteriorating renal function. In contrast to ARVD, the main focus is management of hypertension rather than preventing the decline of renal function, and revascularization is usually by balloon angioplasty without the need for stent insertion.

Vasculitis

Immunosuppressive therapy is indicated in the treatment of the acute phase of Takayasu’s vasculitis, and there is no role for revascularization at this stage. As the disease moves into the chronic stenotic phase, patients are often hypertensive and may have impaired renal function or heart failure as a consequence of arterial stenosis. A retrospective review of 66 patients treated with revascularization reported a cure of hypertension in around 25% of patients and large reductions in blood pressure (45/22 mmHg) and need for anti-hypertensive medications in the remainder, with around a 60%–90% technical success rate. A further prospective study of 27 patients with Takayasu’s-induced RAS reported an improvement in mean eGFR from 76 mL/min to 88 mL/min (P<0.005) following revascularization, and two patients were able to discontinue hemodialysis due to recovery of renal function. There were improvements in blood pressure in all patients, and of congestive cardiac failure symptoms in the latter two affected patients. Although this remains a rare disease, and study numbers are very small, there is a suggestion that revascularization procedures are more likely to lead to an improvement in renal function than in ARVD. The complex etiology of ARVD, with oxidative stress, inflammation, and microvascular disruption all contributing to renal decline, may help to explain this disparity.

Conclusion

There is reasonable evidence to support revascularization as a treatment to improve renal function and hypertension in fibromuscular dysplasia and in RAS following inflammatory arteritis. The situation is certainly much less clear in ARVD. Here, medical therapy remains the cornerstone of treatment and vascular risk factors should be aggressively targeted.
Although questions remain, there seems to be little benefit from revascularization in ARVD, and this should be balanced against the procedural risks in each individual patient.

ARVD is not a disease limited to the renal arteries, but reflects a diffuse process of atherosclerosis and aging. The degree of RAS is a smaller determinant of renal function than the parenchymal injury resulting from atherosclerotic processes of oxidative stress, inflammation, and fibrosis. Established parenchymal damage is often irreversible, so the goal of treatment in ARVD is to limit further renal injury. In this regard, renal function may not be the best endpoint for intervention in ARVD. It is hoped that further analyses will provide clearer guidance as to which patients are most likely to benefit from revascularization procedures, but certainly treatment should be individualized and it should be accepted that there is no single treatment suitable for all in ARVD.

Disclosure
Philip A Kalra was a co-author of the ASTRAL trial. The authors report no other conflicts of interest in this work.

References


